Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Allogene Therapeutics (ALLO) Long-Term Investments (2019 - 2025)

Allogene Therapeutics (ALLO) has disclosed Long-Term Investments for 7 consecutive years, with $8.0 million as the latest value for Q4 2025.

  • Quarterly Long-Term Investments fell 90.03% to $8.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $8.0 million through Dec 2025, down 90.03% year-over-year, with the annual reading at $8.0 million for FY2025, 90.03% down from the prior year.
  • Long-Term Investments hit $8.0 million in Q4 2025 for Allogene Therapeutics, down from $24.9 million in the prior quarter.
  • In the past five years, Long-Term Investments ranged from a high of $378.2 million in Q3 2021 to a low of $1.1 million in Q2 2024.
  • Historically, Long-Term Investments has averaged $78.5 million across 5 years, with a median of $24.3 million in 2022.
  • Biggest five-year swings in Long-Term Investments: soared 9321.59% in 2021 and later tumbled 95.08% in 2022.
  • Year by year, Long-Term Investments stood at $352.2 million in 2021, then crashed by 95.08% to $17.3 million in 2022, then surged by 85.77% to $32.2 million in 2023, then soared by 150.77% to $80.7 million in 2024, then tumbled by 90.03% to $8.0 million in 2025.
  • Business Quant data shows Long-Term Investments for ALLO at $8.0 million in Q4 2025, $24.9 million in Q3 2025, and $29.5 million in Q2 2025.